We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
2 Consumer Staples 1.53%
3 Industrials 0.67%
4 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
51
Xenon Pharmaceuticals
XENE
$6.21B
$25.8M 0.65%
842,498
+71,131
+9% +$2.13M
PHR icon
52
Phreesia
PHR
$769M
$25M 0.63%
950,000
+180,000
+23% +$5.52M
TVTX icon
53
Travere Therapeutics
TVTX
$5.74B
$24.5M 0.62%
951,650
– –
PRTA icon
54
Prothena Corp
PRTA
$468M
$24.3M 0.61%
663,530
+15,800
+2% +$570K
HCAT icon
55
Health Catalyst
HCAT
$129M
$23.9M 0.6%
913,500
+63,300
+7% +$1.8M
RXDX
56
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$23.6M 0.59%
624,307
+5,900
+1% +$233K
AURA icon
57
Aura Biosciences
AURA
$796M
$22.2M 0.56%
1,008,114
– –
BMRN icon
58
BioMarin Pharmaceuticals
BMRN
$13.3B
$20.4M 0.51%
264,500
+500
+0.2% +$41.8K
LFST icon
59
Lifestance Health
LFST
$4.55B
$20.2M 0.51%
2,000,000
– –
CINC
60
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$18.1M 0.46%
+1,031,159
New +$21.2M
RLAY icon
61
Relay Therapeutics
RLAY
$4.37B
$18M 0.45%
601,667
+3,900
+0.7% +$94.6K
LUNG icon
62
Pulmonx
LUNG
$97.9M
$17.4M 0.44%
702,400
+2,400
+0.3% +$62K
OLK
63
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$17.4M 0.44%
986,000
+471,000
+91% +$7.68M
DVAX
64
DELISTED
Dynavax Technologies
DVAX
$17.2M 0.43%
1,590,894
+14,000
+0.9% +$170K
XENT
65
DELISTED
Intersect ENT, Inc
XENT
$15.4M 0.39%
550,000
-390,000
-41% -$10.7M
MRSN
66
DELISTED
Mersana Therapeutics
MRSN
$15M 0.38%
150,233
+20,275
+16% +$2.37M
LEGN icon
67
Legend Biotech
LEGN
$4B
$14.9M 0.38%
411,184
+7,600
+2% +$300K
COLL icon
68
Collegium Pharmaceutical
COLL
$882M
$14.8M 0.37%
725,000
– –
RIGL icon
69
Rigel Pharmaceuticals
RIGL
$778M
$14.7M 0.37%
492,149
+6,129
+1% +$166K
AMRN
70
Amarin Corp
AMRN
$298M
$14.5M 0.37%
220,985
– –
NVCR icon
71
NovoCure
NVCR
$2.02B
$14.5M 0.37%
175,000
– –
RYTM icon
72
Rhythm Pharmaceuticals
RYTM
$7.95B
$14.3M 0.36%
1,237,026
+609,846
+97% +$5.35M
ANAB icon
73
AnaptysBio
ANAB
$1.64B
$13.9M 0.35%
563,300
+24,600
+5% +$745K
GH icon
74
Guardant Health
GH
$22.4B
$13.2M 0.33%
200,000
– –
AMLX icon
75
Amylyx Pharmaceuticals
AMLX
$2.53B
$12.8M 0.32%
+998,307
New +$22.5M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.